COMPANY PRESENTATION 2015
Company Profile Discovery & preclinical stage ADME-Tox CRO Founded in March 2011 Located in Oulu, Finland Serving customers from small Biotechs to Big Pharma Customers in 21 countries on 4 continents
We Make a Difference Specialised in drug metabolism, drug interactions, bioanalysis and pharmacokinetics 100 peer reviewed scientific papers - expertise in ADME & medical biochemistry Tailored and optimised studies - scientific & technical quality with consistency Strong expertise in analytical technologies (LC/MS and NMR) Continuous service development and adaption of customers’ processes
Service Portfolio 1/2 Microsomes, S9, rec-enzymes, hepatocytes In-life part conducted with a partner • • Metabolic stability / clearance Mouse, rat, rabbit, guinea pig, pig, dog, • • Metabolite identification monkey • Extrahepatic metabolism • CYP/UGT/SULT phenotyping • Reactive metabolite screening • PBPK modeling • UPLC/MS/MS or UPLC/HR-MS CYP and UGT Inhibition, TDI/MDI/MBI • • Plasma, urine, feces, brain homogenates, CYP and UGT Induction • • Non-CYP inhibition other tissue homogenates • Method development and validation •
Service Portfolio 2/2 Permeability (Caco2/MDCK) Solubility (buffer & intestinal/gastric fluids) • • P-gp or BCRP (efflux & inhibition) Lipophilicity (logD) • • Uptake transporter assays Plasma protein & brain homogenate binding & in • • vitro binding (RED) Plasma stability, chemical stability • Identification of degradation products or impurities • Cytotoxicity Metabolic stability • • Genotoxicity (AMES, MNT) CYP-inhibition screening • • Cardiotoxicity CYP-induction • • Mechanistic tox assays (oxidative stress, Permeability (Caco2) • • mitochondiral toxicity, caspase 3/7 activity)
www.admescope.com CEO Ari Tolonen ari.tolonen@admescope.com
Recommend
More recommend
